Impact Therapeutics, Inc.

Impact Therapeutics (shanghai), Inc

Other

Suixiong Cai

Ye Edward Tian

Xiaozhu Wang

Feng Yin

Lizhen Wu

Xiuyan Zhang

Ping Huang

Yang Zhang

Lijun Liu

Zheng Meng

Haijun Dong

Guoxiang Wang

Qingbing Xu

Chengyun Gu

Sishun Kang

Shengzhi Chen

Yangzhen Jiang

Sheng Bi

Lei Chen

Yushen Guo

Zenghui Yu

Hongqiang Fei

Dongmei Wang

Zhiqiang Dong

The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A-A, B-B, D-Dand R-Rare defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof

Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R-Rare defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof

The present invention provides a solid pharmaceutical formulation of PARP inhibitors and its use thereof, and more specifically a solid dispersion powder including 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and polymers, wherein the content of polymers is from about 50 wt % to about 80 wt %, and wherein less than 10 wt % of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione is in crystalline form. The present invention also provides a method for preparing the solid dispersion powder, a pharmaceutical composition including the solid dispersion powder and the use of the pharmaceutical composition for treating diseases caused by PARP activity abnormalities.

Solid pharmaceutical formulation of PARP inhibitors and use thereof

The disclosure relates to substituted fused heteroaromatic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: 

Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof

Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D-D, Q, Q, Rare defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer. 

N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof

This disclosure provides a process for preparing 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones, specially provides a method for preparing the compound of Formula I, and the method comprises the step of reacting the compound of Formula II with the compound of Formula A in the presence of a condensation agent, an organic base and an organic solvent by condensation. 

Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones

Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines thereof, represented by the Formula (I) wherein Ar, Ar, R-Rare defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. 

3-aryl-6-aryl-[1,2,4]triazolo[4,3-&#x3b1;]pyridines as inhibitors of cell proliferation and the use thereof

Disclosed are novel 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs thereof, represented by the Formula 1:  wherein Ar, A, R, R-Rare defined herein. Compounds having Formula I are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity, such as cancer.

1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof

Growing community of inventors

Shanghai, China

Suixiong Cai